| Field | Specification |
|---|---|
| UniProt # | |
| Applications | |
| Sensitivity | |
| Detection range | |
| Detection method | |
| Assay time | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
This ELISA kit applies to the in vitro quantitative determination of Human HMGB-1 concentrations in serum, plasma and other biological fluids.
Assay Principle
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human HMGB-1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human HMGB-1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human HMGB-1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human HMGB-1. You can calculate the concentration of Human HMGB-1 in the samples by comparing the OD of the samples to the standard curve.
Performance Specifications
| Sensitivity | 18.75 pg/mL |
|---|---|
| Detection Range | 31.25-2000 pg/mL |
| Total Assay Time | 3 h 30 min |
| Compatible Sample Types | Serum, plasma and other biological fluids |
| Species Reactivity | Human |
| Detection Method | Sandwich |
| Precision (CV) | Both intra-CV and inter-CV are < 10%. |
| Recovery Rate | 80%-120% |
| Storage | 2-8℃,12 months |
✓ Research-Grade Validation
Specificity
This kit recognizes Human HMGB-1 in samples. No significant cross-reactivity or interference between Human HMGB-1 and analogues was observed
Safety & Regulatory
Handle reagents in accordance with institutional biosafety guidelines. Refer to the Safety Data Sheet (SDS) for complete hazard and handling information. Contains components that may require special disposal procedures per local regulations.
This kit is validated for use with Serum, plasma and other biological fluids. For unlisted matrices (e.g., tissue lysate, urine), perform a spike-and-recovery experiment to confirm assay performance before generating reportable data. Sample dilution in the kit's provided diluent is recommended to minimize matrix interference.
The minimum detectable concentration (sensitivity) of this kit is 18.75 pg/mL. Values below this threshold should be reported as below the limit of detection (<LOD) and should not be extrapolated from the standard curve.
The total assay time from sample addition to absorbance reading is approximately 3 h 30 min, including all incubation, wash, and substrate steps. Hands-on time is typically 1–2 hours; most steps involve passive plate incubation. Plan the assay as a single uninterrupted session for best results.
Standard components of this Sandwich ELISA Kit typically include: pre-coated microplate (96-well strip format), lyophilized or liquid recombinant HMGB-1 standard, detection antibody, streptavidin-HRP conjugate, TMB substrate, stop solution, wash buffer concentrate, and sample/standard diluent. Refer to the kit insert or datasheet for the exact component list and storage requirements.
This kit uses colorimetric (TMB/HRP) detection and requires a standard microplate absorbance reader capable of measuring at 450 nm. A reference wavelength of 570 nm or 630 nm is recommended to reduce background. No specialized fluorescence or luminescence reader is needed. Ensure the instrument is calibrated and the plate is clean and free of condensation before reading.
Tissue samples may contain endogenous or exogenous proteases during processing, leading to degradation of extracted proteins. Therefore, it's necessary to add protease inhibitors during processing to ensure the integrity of target proteins. If customers can keep samples cold and handle them quickly during processing, omitting the protease inhibitor may not have a significant effect. After preparation, samples should be tested promptly or immediately aliquoted and frozen at -20°C or -80°C.
What is the range of enzyme activity of your IL-2 freeze-dried powder
What is the principle of adding stop solution to stop color reaction in ELISA experiment?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
A cuproptosis nanocapsule for cancer radiotherapy (2024) Nature Nanotechnology. 10.1038/s41565-024-01784-1
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer (2025) CANCER RESEARCH. 10.1158/0008-5472.CAN-25-0024
Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator (2022) Acta Pharmaceutica Sinica B. 10.1016/j.apsb.2022.12.012
Chemoradiotherapy-Integrated Tumor Cell-Derived Microparticles Mediate Tumor Eradication in Malignant Pleural Effusion (2026) Journal of Extracellular Vesicles. 10.1002/jev2.70277
Tea leaf-derived nanovesicles for ferric-supply-amplified ICD and macrophage reprogramming to boost immunotherapy against head and neck squamous carcinoma (2024) CHEMICAL ENGINEERING JOURNAL. 10.1016/j.cej.2024.158469
A Pyroptosis Radiosensitizer Facilitates Hypoxic Tumor Necrosis (2025) Small. 10.1002/smll.202409594
Lactate-driven ATP6V1B2 lactylation triggers asthmatic inflammation by linking lysosomal dysfunction to mitochondrial ROS-dependent pyroptosis (2026) Redox Biology. 10.1016/j.redox.2026.104059
Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals (2024) Science Advances. 10.1126/sciadv.adp7022
NIR-responsive Cu2???xSe@Fc nanoparticles for photothermal- ferroptosis combination therapy in esophageal cancer (2025) JOURNAL OF NANOBIOTECHNOLOGY. 10.1186/s12951-025-03434-7
Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia (2025) Journal for ImmunoTherapy of Cancer. 10.1136/jitc-2024-011148
Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells (2021) JOURNAL OF NANOBIOTECHNOLOGY. 10.1186/s12951-021-01017-w
Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-line treatment for patients with Undifferentiated Pleomorphic Sarcoma (2026) CLINICAL CANCER RESEARCH. 10.1158/1078-0432.CCR-26-0032
Simultaneous induction of immunogenic cell death and PD-L1 downregulation by bufalin-based nanovaccines for potentiate HCC immunotherapy (2025) Materials Today Bio. 10.1016/j.mtbio.2025.102294
Photothermal-responsive curcumin-loaded copper-based nanocomposites for targeted drug release and combined immunotherapy (2025) JOURNAL OF COLLOID AND INTERFACE SCIENCE. 10.1016/j.jcis.2025.138042
Transient post-operative overexpression of CXCR2 on monocytes of traumatic brain injury patients drives monocyte chemotaxis toward cerebrospinal fluid and enhances monocyte-mediated immunogenic cell death of neurons in vitro (2022) Journal of Neuroinflammation. 10.1186/s12974-022-02535-6
Proteolysis-Targeting Chimera-Doxorubicin Conjugate Nanoassemblies for Dual Treatment of EGFR-TKI Sensitive and Resistant Non-Small Cell Lung Cancer (2025) Acta Biomaterialia. 10.1016/j.actbio.2025.02.012
SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer (2023) PHARMACOLOGICAL RESEARCH. 10.1016/j.phrs.2023.106731
USP5 inhibition stimulates immunogenic ferroptosis that enhances immunotherapy in diffuse large B-cell lymphoma (2026) Cell Communication and Signaling. 10.1186/s12964-025-02617-x
Lappaconitine hydrobromide prevents NLRP3-GSDMD-mediated pyroptosis to alleviate sepsis-induced acute lung injury by enhancing NR1H3 (2026) Journal of Pharmaceutical Analysis. 10.1016/j.jpha.2026.101631
Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma (2018) BIOMATERIALS. 10.1016/j.biomaterials.2018.07.035
Human poliovirus receptor contributes to biliary atresia pathogenesis by exacerbating natural-killer-cell-mediated bile duct injury (2022) LIVER INTERNATIONAL. 10.1111/liv.15457
Suppression of endothelial cell PANoptosis: qingyi decoction targets the TMAO-HMGB1 pathway to mitigate lung injury in acute pancreatitis rats (2026) APOPTOSIS. 10.1007/s10495-025-02212-y
High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments (2020) SCHIZOPHRENIA BULLETIN. 10.1093/schbul/sbaa136
Combining cisplatin with Pinellia pedatisecta Schott lipid-soluble extract induces tumor immunogenic cell death in cervical cancer (2024) PHYTOMEDICINE. 10.1016/j.phymed.2024.155504
Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment (2017) JOURNAL OF CONTROLLED RELEASE. 10.1016/j.jconrel.2017.10.024
